Veoza (fezolinetant) has been officially approved for use on the NHS to help prevent hot flushes in menopausal women, a condition that affects approximately 70% of women during this life stage. This new treatment option is expected to benefit around 500,000 women in England who are seeking relief from these symptoms.

The approval comes as a significant advancement in menopause management, particularly for women for whom hormone replacement therapy (HRT) is unsuitable. Veoza is administered as a once-daily oral tablet and works by blocking nerve pathways in the brain that trigger hot flushes and night sweats.

Helen Knight, a representative from NICE, emphasized the importance of this treatment, stating, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added that this decision will provide much-needed relief for those unable to use HRT.

Dr. Sue Mann, another advocate for women’s health, remarked, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” This sentiment reflects the growing recognition of the need for diverse treatment options in managing menopause symptoms.

Historically, there have been few safe and effective treatments available for menopausal hot flushes, leaving many women to cope with the discomfort without adequate support. The introduction of Veoza represents a pivotal moment in addressing this gap in women’s healthcare.

The NHS has set the list price for Veoza at £44.80 per 28-tablet pack, a cost that NICE has deemed to be cost-effective and valuable for taxpayers. This pricing structure is expected to facilitate access for many women who require this treatment.

As Veoza becomes available, healthcare professionals anticipate that it will empower women to better manage their menopause symptoms and enhance their overall health. While the rollout of this treatment is promising, details remain unconfirmed regarding its availability across all NHS facilities.

The post Veoza Approved for Menopause Treatment in England appeared first on DG News Sport.

Veoza (fezolinetant) has been officially approved for use on the NHS to prevent hot flushes in menopausal women. This significant development is expected to benefit around 500,000 women in England who experience these symptoms, which affect approximately 70% of women undergoing menopause.

Details of the Treatment

The treatment is administered as a once-daily oral tablet, providing a convenient option for women. Veoza works by blocking nerve pathways in the brain that trigger hot flushes and night sweats, offering a new mechanism of action compared to traditional hormone replacement therapy (HRT).

Target Audience and Cost

Veoza is specifically intended for women for whom HRT is unsuitable, addressing a long-standing gap in treatment options. The NHS list price for Veoza is £44.80 per 28-tablet pack, a cost that has been deemed reasonable by the National Institute for Health and Care Excellence (NICE), which found the drug to be cost-effective and valuable for taxpayers.

Expert Opinions

Health experts have welcomed this approval, emphasizing the importance of addressing menopausal symptoms. Helen Knight, a spokesperson for NICE, stated, “We know that menopausal hot flushes and night sweats can have a profound impact on quality of life and significantly affect overall wellbeing.” She added, “This decision will give much-needed relief to those for whom HRT is unsuitable.”

Impact on Women’s Health

Dr. Sue Mann also expressed her support, noting, “Symptoms of menopause including hot flushes and night sweats can affect every part of a woman’s life, so this is very welcome news especially for women who are unable to or don’t wish to take hormone replacement therapy.” She further highlighted that Veoza represents another vital treatment option that could help hundreds of thousands of women manage their symptoms more effectively.

For decades, there have been few safe and effective treatment options for menopausal hot flushes, making the approval of Veoza a noteworthy advancement in women’s health. The introduction of this drug marks a significant step forward in providing alternatives for women seeking relief from menopausal symptoms.

Future Expectations

As Veoza becomes available, healthcare providers and patients alike are optimistic about its potential to improve the quality of life for many women. However, details remain unconfirmed regarding the broader rollout and accessibility of the drug across different regions in England.

The post Veoza Approved for Menopause Treatment in England appeared first on DG News Sport.